Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
222 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Clinical trials
553 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (94)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 1 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | terminated | Phase 1 | 25 | Novo Nordisk A/SINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)(PRINCE) |
| completed |
| Phase 1 / Phase 2 |
| 37 |
| Peter MacCallum Cancer Centre, AustraliaOTHER |
| 1 |
| Jul 28, 2023 |
| clinicaltrials |
| NCT05558956 | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | unknown | Early Phase 1 | 100 | BAMF HealthOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05955209 | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 21, 2023 | clinicaltrials |
| NCT03569280 | Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | completed | Phase 1 | 16 | Kangpu Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05549778 | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC(PEACe) | completed | Phase 1 / Phase 2 | 12 | Jiangnan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04179396 | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)(RAMP) | completed | Phase 1 | 8 | pharmaand GmbHINDUSTRY | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04676607 | SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT03381326 | CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.(IRSTB030) | unknown | — | 104 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05607693 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | unknown | Phase 1 | 52 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 22 | Calibr, a division of Scripps ResearchOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03406858 | Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05823402 | Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)(SPECTacular) | unknown | N/A | 30 | BAMF HealthOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | withdrawn | Phase 1 | 0 | Syneos HealthOTHER | 0 | Apr 28, 2023 | clinicaltrials |
| NCT04962880 | HRR Prevalence in LatAm PROSPECT Study(PROSPECT) | completed | — | 388 | AstraZenecaINDUSTRY | 7 | Apr 14, 2023 | clinicaltrials |
| NCT05533203 | Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) | unknown | Phase 1 | 24 | Shanghai Humantech Biotechnology Co. LtdINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02833883 | Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | completed | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04825652 | 177Lu-PSMA-617 Managed Access Program for mCRPC Patients | no longer available | — | — | Advanced Accelerator ApplicationsINDUSTRY | 0 | Jan 13, 2023 | clinicaltrials |
| NCT02907372 | Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer(COG-PRO) | completed | N/A | 163 | Centre Francois BaclesseOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT02669147 | A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC(DELC) | completed | — | 160 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 0 | Dec 28, 2022 | clinicaltrials |
| NCT03526562 | Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients | completed | N/A | 9 | University Hospital, GhentOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02598895 | Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway | completed | Phase 2 | 14 | University of WashingtonOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT03247010 | Bone Marrow Suppression and Recovery During Radionuclide Treatment | completed | — | 68 | Rigshospitalet, DenmarkOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | completed | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT03601143 | Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients(PEARL) | unknown | — | 120 | Technical University of MunichOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04509557 | [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. | completed | Phase 1 | 30 | FutureChemINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients(ESCALATE) | terminated | Phase 3 | 23 | MANA RBMOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02346526 | A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 22 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer | terminated | Phase 1 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2022 | clinicaltrials |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | terminated | Phase 1 | 16 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 11, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT01517802 | A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | completed | Phase 3 | 32 | Janssen Research & Development, LLCINDUSTRY | 7 | May 10, 2022 | clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05327621 | Pamiparib in mCRPC With HRD or BRCA1/2 Mutation | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03071328 | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers | completed | Early Phase 1 | 10 | Duke UniversityOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04862091 | Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer | completed | Phase 2 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05262608 | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation(PROspect) | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2023source: clinicaltrials